BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,615.80
- Market cap
- ₹73,824 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 50.9×Sector 48.6×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Product Launch
Glenmark's US arm launched an authorized generic of INLYTA (axitinib) tablets. The product addresses a sizeable US market with established originator sales.
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.
Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Other business update announcements
All →Cipla Business Update
Cipla's US subsidiary InvaGen received a No Action Indicated classification from USFDA for its October 2026 inspection. No penalty or monetary impact was disclosed.
Purple Wave Infocom Business Update
Purple Wave Infocom received ZED Gold Certification under the MSME scheme for its Manesar manufacturing unit. The certificate is valid for three years from September 2026.
ACME Solar Holdings Business Update
ACME Solar commissioned a further 52.32 MW / 209.28 MWh of BESS at its Bikaner FDRE project, taking cumulative BESS capacity to 247.67 MW. COD is November 19, 2026, with the PPA signed with SJVN.
- BESS discharge capacity
- 52.32 MW
TSC India Business Update
TSC India reported 21.74% YoY growth in H1 FY27 gross transaction value, with registered agents up 37.13% to 4,114 and bookings up 5.92%. The release is a business update with no revenue or profit table.
Ashoka Buildcon Business Update
Ashoka Buildcon was declared lowest bidder (L-1) for an NHAI EPC project at a quoted price of Rs.1,465 Crore excluding GST. No contract has been awarded yet.
- Value
- ₹1,465 Cr
- From
- National Highways Authority of India (NHAI)
- Execution
- 18 months
Excelsoft Technologies Business Update
Excelsoft Technologies won the STPI IT Export Award for FY 2025–26, its second consecutive year, as Mysuru's best IT/ITES performer. The recognition was presented at the Bengaluru Tech Summit on 17 November 2026.